Back to News

GVK Biosciences Completes 10 years in Collaboration with Nuevolution

Enhanced productivity metrics over 10 years

Value creation for Nuevolution with complex problem solving capabilities

Focus to further improve on timely completion & cost effective solution within QC framework

Hyderabad, India — November 10, 2017 — GVK BIO, a leading Contract Research & Development (R&D) Organization that services the global Biopharma industry, known for its customer focus, today celebrated 10 years of research and development collaboration with Denmark-based Nuevolution.

Over last 10 years, GVK BIO and Nuevolution have collaborated on projects that pan across integrated Discovery and Development. The collaboration journey with Nuevolution has witnessed enhanced productivity metrics, problem solving, innovation and more timely completion of projects by supporting the discovery pipeline of Nuevolution. Another dimension of scientific contribution was ability to handle complex projects, leveraging problem solving capabilities while keeping a focus on customer requirements.

Speaking on the occasion of this celebration, Dr. Sudhir Kumar Singh, President – Discovery and Development Services, GVK BIO said “The collaboration project with Nuevolution showcases our R&D capabilities, our delivery capabilities and our customer focus. Over last 10 years, both companies have strived hard to handle complex scientific problems and leverage innovation strengths & safety processes to deliver significant value to Nuevolution.”

Dr Thomas Franch, CSO of Nuevolution commented “We have enjoyed a very good working relationship over the last 10 years where GVK BIO have contributed and added value to our activities.”

About GVK BIO
GVK BIO, a leading Contract Research & Development (R&D) Organization that services the global Biopharma industry; is headquartered in Hyderabad, India with operations in four sites including California, USA. Established in 2001, GVK BIO has over 16 years of rich experience across the Research and Development value chain with a focus on speed and quality. Our team of over 2000 highly qualified scientists, backed by well-defined and scalable processes, modern facilities and a strong customer-centric partnering approach, focus on bringing our customers’ products to market. We partner with reputed global academic institutions and research laboratories to find efficient, cost-effective and innovative solutions to their Research and Development challenges.

About Nuevolution
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immune-oncology. More information about Nuevolution can be found at www.nuevolution.com